All News
How to patients with rheumatic diseases consume online health information?
78% used internet for health information
50% use it atleast a month
66% found online information superior
41% used social media!
80% using it to find treatment optio ns!
@rheumnow #EULAR2025 https://t.co/ZcjwPaqsjT
Dr. John Cush RheumNow ( View Tweet)
Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025 @RheumNow https://t.co/yzQVt1fLKW https://t.co/kiX6kPPQP5
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2025 in numbers
💫5125 abstracts submitted from 95 countries
💫177 scientific sessions
💫350 speakers from 45 nations
💫Balanced gender split of speakers & chairpersons
💫Fresh sessions format
💫Integration of European Workshop for Rheum Research https://t.co/7WoknFuVLL
Dr. John Cush RheumNow ( View Tweet)
HLA-B27 Testing in Practice
A single center study shows HLA-B27 testing is often performed by both by rheumatologists and nonrheumatologists for a wide array of reasons and often along with other serologic tests. Optimal use of HLA-B27 testing has yet to be defined. https://t.co/oq7GNhzwZd
Dr. John Cush RheumNow ( View Tweet)
TONIX pharm presented two phase 3 RCTs at #EULAR2025 demonstrating efficacy of sublingual cylcobenzaprine at bedtime in w/ significant reductions in Fibromyalgia pain scores. TNX-102 SL could be the 1st new FM drug to be FDA approved in >15 yrs. PDUFA (decision) date is 8.15.25. https://t.co/XNd8uYLQsJ
Dr. John Cush RheumNow ( View Tweet)
Assessment of Peripheral Arthritis in Spondyloarthritis
Dr. Antoni Chan talks with Dr. Dafne Capelusnik about abstract POS0257 presented at the 2025 EULAR meeting in Barcelona.
https://t.co/E6l6qvNnox https://t.co/gLbMjF406q
Dr. John Cush RheumNow ( View Tweet)
Trends and Innovations from Barcelona (6.20.2025)
Dr. Jack Cush reviews highlights, trends and novel studies from EULAR 2025 in Barcelona from last week.
https://t.co/iEiQI8GACt https://t.co/X27CuZb5wH
Dr. John Cush RheumNow ( View Tweet)
Simple Measures are Effective in Knee Osteoarthritis
Knee braces, water therapy and exercise are the most promising non-drug therapies for treating knee osteoarthritis, according to a new meta-analysis publishing June 18, 2025 in the open-access journal PLOS One by Yuan Luo of https://t.co/4VQpKQJwXu
Dr. John Cush RheumNow ( View Tweet)
IL-17 inhibitors - Long-term Extensions and Uveitis
Dr. Peter Nash offers his perspective on data presented at the 2025 EULAR meeting in Barcelona.
https://t.co/eQd0TcQn76 https://t.co/6Zog4LC8Aj
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, tibia, LOM of fingers & elbows. Denied DM, Raynauds. Worse after tennis, better w/ steroids. Increased ANA, eosinophils, CRP, aldolase - your Dx? https://t.co/ppuzIB4iRf
Dr. John Cush RheumNow ( View Tweet)
Eular 2025 PsA Topic Panel
https://t.co/wJ08aKGZfJ https://t.co/6OvkIeOT76
Dr. John Cush RheumNow ( View Tweet)
EULAR 2025 – SpA Panel Discussion
Leading rheumatology experts discuss the latest research, treatment advances, and clinical insights in axial spondyloarthritis. Hear what’s new from EULAR 2025 and what it means for improving patient outcomes.
https://t.co/AcwtseWBi0 https://t.co/MzEN0VtLx6
Dr. John Cush RheumNow ( View Tweet)
A new mechanism of action in SARD-ILD
Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a new mechanism of action to treat lung fibrotic diseases. FIBRONEER-ILD, the Phase 3 RCT of Nerandomilast in patients with progressive pulmonary fibrosis, was https://t.co/goikCwJa2x
Dr. John Cush RheumNow ( View Tweet)
Not All About B Cells: Myeloid Related Inflammation in Lupus Pathogenesis
Dr. Andrea Fava shares his perspectives from the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/8Lh02c3sy4 https://t.co/XX7wKovD9u
Dr. John Cush RheumNow ( View Tweet)
Secukinumab & Uveitis = Unclear? Post hoc study of 11 SEC RCTs finds lower uveitis risk in AxSpA (N 1980; SEC 150 1.29/100PYs vs 1.72/100PY in PBO), but not in PsA (N 2453; SEC 300 0.71/100PY vs zero w/ placebo) https://t.co/Gv9HheBU7l https://t.co/SlnrLRwmmn
Dr. John Cush RheumNow ( View Tweet)
Nurse-Led Treat-to-Target Clinics
New studies shared at the 2025 annual EULAR congress in Barcelona highlight the benefits that nurse-led care can bring for both patients and healthcare systems.
https://t.co/sV8IHhnwbm https://t.co/IrJKvceyez
Dr. John Cush RheumNow ( View Tweet)
#EULAR2025 TriNetX database study indicated that fibromyalgia patients who used glucagon-like peptide-1 (GLP-1) receptor agonist drugs were less likely to use opioids and to report pain, fatigue, and malaise compared with propensity-matched non-users https://t.co/ftm93VwW65 https://t.co/2wloutoX8a
Dr. John Cush RheumNow ( View Tweet)
Expanding the IL-17 Therapeutic Landscape
IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. https://t.co/Q7Thp1HJAL
Dr. John Cush RheumNow ( View Tweet)
The Value of Kidney Biopsy in Autoimmune Diseases
Dr. Andrea Fava shares his perspective from the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/CA6Ak2scKb https://t.co/EK5wdpbzrl
Dr. John Cush RheumNow ( View Tweet)
ALTO: Long-term Outcomes of APIPPRA
Dr. Mrinalini Dey interviews Professor Andrew Cope about abstract OP0004, on the long term outcome of APIPPRA patients - the ALTO study, at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/9wVZSXbi6r https://t.co/fm77qDoTwm
Dr. John Cush RheumNow ( View Tweet)
